Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study

[1]  V. Wong,et al.  Geographical similarity and differences in the burden and genetic predisposition of NAFLD , 2022, Hepatology.

[2]  S. Ahn,et al.  Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria , 2022, Frontiers in Medicine.

[3]  K. Chayama,et al.  Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020 , 2021, Journal of Gastroenterology.

[4]  Y. Eguchi,et al.  Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease , 2021, Alimentary pharmacology & therapeutics.

[5]  H. Takagi,et al.  Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score , 2021, JGH open : an open access journal of gastroenterology and hepatology.

[6]  K. Kashiwabara,et al.  Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study , 2021, Internal medicine.

[7]  M. Moriguchi,et al.  Effect of pemafibrate on fatty acid levels and liver enzymes in non‐alcoholic fatty liver disease patients with dyslipidemia: A single‐arm, pilot study , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

[8]  A. Lefor,et al.  Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease , 2020, Clinical and experimental hepatology.

[9]  H. Isomoto,et al.  Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease. , 2020, Yonago acta medica.

[10]  H. Aburatani,et al.  Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content , 2020, Scientific Reports.

[11]  L. Hodson,et al.  Non-alcoholic fatty liver disease in adults: Current concepts in etiology, outcomes and management. , 2019, Endocrine reviews.

[12]  S. Selph,et al.  Diabetes drugs for nonalcoholic fatty liver disease: a systematic review , 2019, Systematic Reviews.

[13]  V. Aidinis,et al.  Autotaxin and chronic inflammatory diseases. , 2019, Journal of autoimmunity.

[14]  A. Zarbock,et al.  Platelets in Inflammation and Resolution , 2019, The Journal of Immunology.

[15]  A. Scheen,et al.  Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. , 2019, Diabetes & metabolism.

[16]  S. Yamashita,et al.  Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases , 2019, Journal of atherosclerosis and thrombosis.

[17]  E. Bugianesi,et al.  NASH in Lean Individuals , 2019, Seminars in Liver Disease.

[18]  N. Tanaka,et al.  Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease , 2018, World journal of gastroenterology.

[19]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[20]  J. Luyendyk,et al.  Platelets as Modulators of Liver Diseases , 2017, Seminars in Thrombosis and Hemostasis.

[21]  F. Gonzalez,et al.  Targeting nuclear receptors for the treatment of fatty liver disease , 2017, Pharmacology & therapeutics.

[22]  N. Ohkohchi,et al.  Platelets in liver disease, cancer and regeneration , 2017, World journal of gastroenterology.

[23]  A. Nakajima,et al.  Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis , 2017, Scientific Reports.

[24]  S. Bellentani.  The epidemiology of non‐alcoholic fatty liver disease , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[25]  Yuanda Song,et al.  Overexpression of autotaxin is associated with human renal cell carcinoma and bladder carcinoma and their progression , 2016, Medical Oncology.

[26]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[27]  Marco Maggioni,et al.  Statin use and non-alcoholic steatohepatitis in at risk individuals. , 2015, Journal of hepatology.

[28]  D. Mikhailidis,et al.  Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. , 2015, World journal of gastroenterology.

[29]  Philippe Lefebvre,et al.  Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. , 2015, Journal of hepatology.

[30]  S. Kersten.  Integrated physiology and systems biology of PPARα , 2014, Molecular metabolism.

[31]  H. Ikeda,et al.  Autotaxin in liver fibrosis. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[32]  S. Kōzuma,et al.  Serum autotaxin measurements in pregnant women: application for the differentiation of normal pregnancy and pregnancy-induced hypertension. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[33]  Jonathan C. Cohen,et al.  Human Fatty Liver Disease: Old Questions and New Insights , 2011, Science.

[34]  N. Sasahira,et al.  Specific increase in serum autotaxin activity in patients with pancreatic cancer. , 2011, Clinical biochemistry.

[35]  A. Burt,et al.  Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease , 2022 .

[36]  M. Bollen,et al.  Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. , 2009, Cancer letters.

[37]  A. Sanyal,et al.  Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[38]  J. George,et al.  Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. , 2008, Molecular pharmaceutics.

[39]  S. Pol,et al.  FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest , 2007, Hepatology.

[40]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[41]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[42]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.